Efficacy of masitinib in dogs with steroid-resistant inflammatory bowel disease
Fabio Procoli DMV MRCVS, Senior Clinical Training Scholar in Small Animal Internal Medicine
Karin Allenspach Dr.med.vet. PhD DECVIM-CA MRCVS, Senior Lecturer in Small Animal Internal Medicine
Masitinib is a protein tyrosine kinase inhibitor licensed for the use in dogs with mast cell tumours, where it has proven efficacy. There also reports that this drug can decrease inflammation in people with several immune mediated disorders, including IBD.
The Veterinary Clinical Sciences at the Royal Veterinary College is performing a clinical trial to evaluate the clinical efficacy of masitinib as a sole treatment for canine IBD in steroid-refractory cases over a period of 8 weeks.
Further details can be found in the SAMSOC wiki.
Other projects listed
As part of the LUPA initiative ( http://www.eurolupa.org ), the Royal Veterinary College, University of London and the Universities of Manchester and Uppsala are collaborating to investigate the genetic...
Exocrine Pancreatic insufficiency (EPI) Treatment Study Aran Mas DVM MRCVS P-J.M.Noble BSc BVM&S PhD MRCVS, A.J.German BVSc PhD CertSAM DipECVIM-CA MRCVS
We are currently looking at the predisposition of Birman cats to congenital portosystemic shunts. The project is being run by Angie Hibbert and Professor Tim Gruffydd-Jones at the Feline Centre Bristol
Stijn Neissen RVC
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.